Search
Terns Pharmaceuticals Inc
TERNAdd to Watchlist
52.950USD
0.0000.00%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
6.12BMarket Cap
LossP/E TTM
More Details of Terns Pharmaceuticals Inc Company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Terns Pharmaceuticals Inc Info
Ticker SymbolTERN
Company nameTerns Pharmaceuticals Inc
IPO dateFeb 05, 2021
CEOBurroughs (Amy L)
Number of employees59
Security typeOrdinary Share
Fiscal year-endFeb 05
Address1065 East Hillsdale Blvd., Suite 100
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16505255535
Websitehttps://ternspharma.com/
Ticker SymbolTERN
IPO dateFeb 05, 2021
CEOBurroughs (Amy L)
Company Executives of Terns Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Independent Director
Independent Director
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
FAQs
Who are the top five shareholders of Terns Pharmaceuticals Inc?
The top five shareholders of Terns Pharmaceuticals Inc are: Mr. David Fellows
How many institutions hold shares of Terns Pharmaceuticals Inc (TERN)?
As of 2026Q1, 478 institutions hold shares of Terns Pharmaceuticals Inc, with a combined market value of approximately 133.90M, accounting for 115.93% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 29441972.00.
